Cargando…

Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients

Immunotherapy, including therapeutic vaccines, is increasingly being developed for patients with high-grade glioma, and combinations of immunotherapies and synergy with standard of care are being investigated. In this regard, bevacizumab (BEV) has been shown to synergize with immunotherapy in precli...

Descripción completa

Detalles Bibliográficos
Autores principales: Boydell, Emma, Marinari, Eliana, Migliorini, Denis, Dietrich, Pierre-Yves, Patrikidou, Anna, Dutoit, Valérie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520681/
https://www.ncbi.nlm.nih.gov/pubmed/30986995
http://dx.doi.org/10.3390/cancers11040464
_version_ 1783418786435563520
author Boydell, Emma
Marinari, Eliana
Migliorini, Denis
Dietrich, Pierre-Yves
Patrikidou, Anna
Dutoit, Valérie
author_facet Boydell, Emma
Marinari, Eliana
Migliorini, Denis
Dietrich, Pierre-Yves
Patrikidou, Anna
Dutoit, Valérie
author_sort Boydell, Emma
collection PubMed
description Immunotherapy, including therapeutic vaccines, is increasingly being developed for patients with high-grade glioma, and combinations of immunotherapies and synergy with standard of care are being investigated. In this regard, bevacizumab (BEV) has been shown to synergize with immunotherapy in preclinical studies of glioma and in other tumour entities. Here, we conducted a post-hoc exploratory study to evaluate the effect of the IMA950/poly-ICLC peptide vaccine on subsequent BEV administration in high-grade glioma patients. 16 IMA950-vaccinated and 40 non-vaccinated patients were included. At initial diagnosis, patients benefited from surgery and chemoradiation. At first or subsequent recurrence, patients received 10mg/kg of BEV every 2–3 weeks. Primary endpoints were overall survival (OS) and progression-free survival (PFS) from BEV initiation. IMA950-vaccinated patients did not show improved response to BEV as compared to non-vaccinated patients: there was no difference in median PFS (2.6 vs. 4.2 months for vaccinated and control patients, respectively, p = 0.50) nor in median OS (7.8 vs. 10.0 months for vaccinated and control patients, respectively, p = 0.69). In conclusion, potential synergy of BEV and therapeutic vaccines, when administered sequentially, has yet to be established in the clinical setting of GBM recurrence. Potential synergy of concomitant administration should be tested in future trials.
format Online
Article
Text
id pubmed-6520681
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-65206812019-05-31 Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients Boydell, Emma Marinari, Eliana Migliorini, Denis Dietrich, Pierre-Yves Patrikidou, Anna Dutoit, Valérie Cancers (Basel) Article Immunotherapy, including therapeutic vaccines, is increasingly being developed for patients with high-grade glioma, and combinations of immunotherapies and synergy with standard of care are being investigated. In this regard, bevacizumab (BEV) has been shown to synergize with immunotherapy in preclinical studies of glioma and in other tumour entities. Here, we conducted a post-hoc exploratory study to evaluate the effect of the IMA950/poly-ICLC peptide vaccine on subsequent BEV administration in high-grade glioma patients. 16 IMA950-vaccinated and 40 non-vaccinated patients were included. At initial diagnosis, patients benefited from surgery and chemoradiation. At first or subsequent recurrence, patients received 10mg/kg of BEV every 2–3 weeks. Primary endpoints were overall survival (OS) and progression-free survival (PFS) from BEV initiation. IMA950-vaccinated patients did not show improved response to BEV as compared to non-vaccinated patients: there was no difference in median PFS (2.6 vs. 4.2 months for vaccinated and control patients, respectively, p = 0.50) nor in median OS (7.8 vs. 10.0 months for vaccinated and control patients, respectively, p = 0.69). In conclusion, potential synergy of BEV and therapeutic vaccines, when administered sequentially, has yet to be established in the clinical setting of GBM recurrence. Potential synergy of concomitant administration should be tested in future trials. MDPI 2019-04-02 /pmc/articles/PMC6520681/ /pubmed/30986995 http://dx.doi.org/10.3390/cancers11040464 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Boydell, Emma
Marinari, Eliana
Migliorini, Denis
Dietrich, Pierre-Yves
Patrikidou, Anna
Dutoit, Valérie
Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients
title Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients
title_full Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients
title_fullStr Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients
title_full_unstemmed Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients
title_short Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients
title_sort exploratory study of the effect of ima950/poly-iclc vaccination on response to bevacizumab in relapsing high-grade glioma patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520681/
https://www.ncbi.nlm.nih.gov/pubmed/30986995
http://dx.doi.org/10.3390/cancers11040464
work_keys_str_mv AT boydellemma exploratorystudyoftheeffectofima950polyiclcvaccinationonresponsetobevacizumabinrelapsinghighgradegliomapatients
AT marinarieliana exploratorystudyoftheeffectofima950polyiclcvaccinationonresponsetobevacizumabinrelapsinghighgradegliomapatients
AT migliorinidenis exploratorystudyoftheeffectofima950polyiclcvaccinationonresponsetobevacizumabinrelapsinghighgradegliomapatients
AT dietrichpierreyves exploratorystudyoftheeffectofima950polyiclcvaccinationonresponsetobevacizumabinrelapsinghighgradegliomapatients
AT patrikidouanna exploratorystudyoftheeffectofima950polyiclcvaccinationonresponsetobevacizumabinrelapsinghighgradegliomapatients
AT dutoitvalerie exploratorystudyoftheeffectofima950polyiclcvaccinationonresponsetobevacizumabinrelapsinghighgradegliomapatients